Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZ.F

CA1806342061

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - 12:16:04 2026-02-27 EST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Claritas Pharmaceuticals, Inc. -.--% -

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap 5.37M 3.83M 3.34M 3.16M 2.87M 368M 5.39M 37.8M 14.59M 187M 14.4M 14.08M 602M P/E 2019
-0.74x
P/E 2020 0.13x
Enterprise Value 6.29M 4.49M 3.91M 3.7M 3.36M 431M 6.31M 44.27M 17.09M 219M 16.86M 16.49M 705M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
99.74%
Yield 2019 *
-
Yield 2020 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.4
10 years 0
Extreme 1.0E-6
15.31
Manager TitleAgeSince
Chief Executive Officer 76 2017-06-20
Director of Finance/CFO 58 2018-06-28
Director TitleAgeSince
Chairman 76 2021-03-17
Date Insider Type Main position Quantity % Market Cap. Importance
10/11/21 Buy 118,000 0.3332%
10/11/21 Buy 152,500 0.4307%
10/11/21 Buy 24,500 0.0692%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 37
+0.11%+2.71%+0.33%+28.59% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%+0.67%+11.79%+40.51% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+8.12%+22.15%+38.93% 15.32B
-3.28%-3.07%-8.54%-37.61% 13.09B
Average -1.06%+0.66%+51.55%+100.90% 26.4B
Weighted average by Cap. -1.11%+0.87%+66.22%+122.99%

Financials

2019 2020
Net sales - -
Net income -21.21M -15.14M -13.2M -12.47M -11.32M -1.45B -21.3M -149M -57.63M -739M -56.88M -55.62M -2.38B 4.21M 3.01M 2.62M 2.47M 2.25M 288M 4.23M 29.64M 11.44M 147M 11.29M 11.04M 472M
Net Debt 704K 503K 438K 414K 376K 48.22M 707K 4.96M 1.91M 24.52M 1.89M 1.85M 78.89M 920K 657K 573K 541K 491K 63.02M 924K 6.48M 2.5M 32.04M 2.47M 2.41M 103M
Logo Claritas Pharmaceuticals, Inc.
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Employees
-
  1. Stock Market
  2. Stocks
  3. CLAZ.F Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!